Table 1.
Patient demographics and tumor characteristics
| Characteristics | Number (%) |
|---|---|
| Age (years) | 60.11 ± 9.62 |
| Gender | |
| Male | 96/209 (45.9%) |
| Female | 113/209 (54.1%) |
| Family tumor history | |
| None | 194/209 (92.8%) |
| Lung cancer | 9/209 (4.3%) |
| Gastrointestinal cancer | 3/209 (1.4%) |
| Other† | 3/209 (1.4%) |
| Clinical symptoms | |
| Asymptomatic | 75/209 (35.9%) |
| Symptomatic | 134/209 (64.1%) |
| Lobe | |
| RUL | 73/209 (34.9%) |
| ML | 19/209 (9.1%) |
| RLL | 38/209 (18.2%) |
| LUL | 45/209 (21.5%) |
| LLL | 34/209 (16.3%) |
| TNM stage | |
| IA | 163/209 (77.9%) |
| IB | 8/209 (3.8%) |
| IIA | 30/209 (14.4%) |
| IIB | 8/209 (3.8%) |
| Surgical method | |
| VATS | 140/209 (67.0%) |
| Conventional thoracotomy | 45/209 (21.5%) |
| Da Vinci surgical robotic system | 24/209 (11.5%) |
| Operation selection | |
| Lobectomy | 181/209 (86.6%) |
| Segmentectomy | 6/209 (2.9%) |
| Wedge resection | 22/209 (10.5%) |
| Histologic subtype | |
| Lepidic | 38/209 (18.2%) |
| Acinar | 113/209 (54.1%) |
| Papillary | 36/209 (17.2%) |
| Micropapillary | 1/209 (0.5%) |
| Solid | 21/209 (10.0%) |
| EGFR status | |
| EGFR+ | 126/209 (60.3%) |
| L858R | 67/126 (53.2%) |
| 19 deletion | 50/126 (39.6%) |
| L858R/T790M | 1/126 (0.8%) |
| L858R /19 deletion | 1/126 (0.8%) |
| Exon21 L861Q | 2/126 (1.6%) |
| Exon18 G719X | 3/126 (2.4%) |
| Exon20 S768I | 2/126 (1.6%) |
| EGFR− | 83/209 (39.7%) |
†
Other includes bladder cancer, gynecological oncology. EGFR, epidermal growth factor receptor; LLL, left lower lobe; LUL, left upper lobe; ML, middle lobe; RLL, right lower lobe; RUL, right upper lobe; TNM, tumor node metastasis; VATS, video‐assisted thoracoscopic surgery.